- Home
- DYAI vs COEP Comparison
DYAI vs COEP Comparison
Compare DYAI & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- COEP
- Stock Information
- Founded
- DYAI 1979
- COEP 2017
- Country
- DYAI United States
- COEP United States
- Employees
- DYAI N/A
- COEP N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYAI Health Care
- COEP Health Care
- Exchange
- DYAI Nasdaq
- COEP Nasdaq
- Market Cap
- DYAI 28.3M
- COEP 27.4M
- IPO Year
- DYAI 2004
- COEP N/A
- Fundamental
- Price
- DYAI $1.01
- COEP $10.68
- Analyst Decision
- DYAI Strong Buy
- COEP
- Analyst Count
- DYAI 1
- COEP 0
- Target Price
- DYAI $6.00
- COEP N/A
- AVG Volume (30 Days)
- DYAI 58.3K
- COEP 44.6K
- Earning Date
- DYAI 08-12-2025
- COEP 08-15-2025
- Dividend Yield
- DYAI N/A
- COEP N/A
- EPS Growth
- DYAI N/A
- COEP N/A
- EPS
- DYAI N/A
- COEP N/A
- Revenue
- DYAI $3,554,344.00
- COEP $62,874.00
- Revenue This Year
- DYAI $22.56
- COEP N/A
- Revenue Next Year
- DYAI $30.95
- COEP N/A
- P/E Ratio
- DYAI N/A
- COEP N/A
- Revenue Growth
- DYAI 57.59
- COEP N/A
- 52 Week Low
- DYAI $0.91
- COEP $2.31
- 52 Week High
- DYAI $2.20
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- DYAI 55.41
- COEP 68.20
- Support Level
- DYAI $0.91
- COEP $7.25
- Resistance Level
- DYAI $1.03
- COEP $11.70
- Average True Range (ATR)
- DYAI 0.05
- COEP 0.64
- MACD
- DYAI 0.01
- COEP 0.34
- Stochastic Oscillator
- DYAI 83.00
- COEP 84.27
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.